Joe O'Sullivan, MD, on utilizing radium-223 treatment earlier in patients with metastatic castration-resistant prostate cancer (mCRPC).
Joe O'Sullivan, MD
Advertisement
Articles by Joe O'Sullivan, MD
Advertisement
Latest Updated Articles
Dr. Joe O'Sullivan on Utilizing Radium-223 Treatment Earlier in Patients With mCRPCPublished: December 2nd 2015 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
